Verrica Pharmaceuticals Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Verrica Pharmaceuticals Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.58M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $7.57M | Mar 11, 2026 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.57M | Mar 11, 2025 |
| FY2024 | Dec 31, 2023 | $5.12M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $9.03M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $12.00M | Mar 6, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.89M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($76.58M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($67.00M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($24.49M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($35.08M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($42.69M) | Mar 2, 2022 |
| FY2019 | Dec 31, 2019 | ($7.64M) | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | ($6.09M) | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | ($7.00M) | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | ($7.48M) | Mar 13, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.19M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($65.92M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($65.76M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($21.30M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($30.91M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($40.18M) | Mar 2, 2022 |
| FY2019 | Dec 31, 2019 | ($7.99M) | Mar 13, 2020 |
| FY2019 | Sep 30, 2019 | ($6.54M) | Mar 13, 2020 |
| FY2019 | Jun 30, 2019 | ($7.52M) | Mar 13, 2020 |
| FY2019 | Mar 31, 2019 | ($8.03M) | Mar 13, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.13M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $54.13M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $81.60M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $44.72M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $80.13M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $74.15M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $68.42M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $91.91M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $9.08M | Mar 7, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.39M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $63.99M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $61.83M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $4.69M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $47.52M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $41.17M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $3.41M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $2.48M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $616.0K | Mar 7, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.74M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($9.86M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $19.76M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $40.03M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $32.61M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $32.99M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $65.02M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $89.43M | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | ($7.04M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($2.66M) | Mar 7, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 6, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 6, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.15M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $46.33M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $69.55M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $34.27M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $15.75M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $10.69M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $9.24M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $10.27M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $8.66M | Mar 7, 2019 |
| FY2018 | Dec 31, 2016 | $527.0K | Mar 7, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $30.98M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $42.87M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Feb 29, 2024 |